{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:47:18Z","timestamp":1776725238472,"version":"3.51.2"},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1055\/a-2751-3243","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:49:41Z","timestamp":1771458581000},"page":"296-299","source":"Crossref","is-referenced-by-count":1,"title":["Keratoconjunctivitis after Tralokinumab for Severe Atopic Dermatitis \u2013 A Case Report"],"prefix":"10.1055","volume":"243","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2037-4766","authenticated-orcid":false,"given":"Sadiq","family":"Said","sequence":"additional","affiliation":[{"name":"Augenklinik Wettingen, Switzerland"},{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia","family":"Hertkorn","sequence":"additional","affiliation":[{"name":"Augenklinik Wettingen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Knecht-B\u00f6sch","sequence":"additional","affiliation":[{"name":"Augenklinik Wettingen, Switzerland"},{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Knecht-B\u00f6sch","sequence":"additional","affiliation":[{"name":"Augenklinik Wettingen, Switzerland"},{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","article-title":"ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children","volume":"34","author":"A Wollenberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","article-title":"Atopic dermatitis","volume":"405","author":"E Guttman-Yassky","year":"2025","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/all.12619","article-title":"Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities","volume":"70","author":"C G Mortz","year":"2015","journal-title":"Allergy"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2500\/aap.2012.33.3569","article-title":"Epidemiology of atopic dermatitis: a review","volume":"33","author":"S P DaVeiga","year":"2012","journal-title":"Allergy Asthma Proc"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/all.12270","article-title":"New insights into the epidemiology of childhood atopic dermatitis","volume":"69","author":"C Flohr","year":"2014","journal-title":"Allergy"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"964","DOI":"10.2340\/00015555-3257","article-title":"Burden of Atopic Dermatitis in Swedish Adults: A Population-based Study","volume":"99","author":"G Theodosiou","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/bjd\/ljad339","article-title":"Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study","volume":"190","author":"J Tian","year":"2023","journal-title":"Br J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","article-title":"Pathophysiology of atopic dermatitis: Clinical implications","volume":"40","author":"J Kim","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","article-title":"Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations","volume":"132","author":"AAAAI\/ACAAI JTF Atopic Dermatitis Guideline Panel","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.5863\/1551-6776-29.6.587","article-title":"Atopic Dermatitis: A Review of Diagnosis and Treatment","volume":"29","author":"J Jeskey","year":"2024","journal-title":"J Pediatr Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","article-title":"Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials","volume":"152","author":"A WL Chu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5114\/ada.2018.79445","article-title":"Ophthalmic manifestations of atopic dermatitis","volume":"37","author":"M Pietruszynska","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1111\/all.15811","article-title":"Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition","volume":"78","author":"E L Simpson","year":"2023","journal-title":"Allergy"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1111\/all.16182","article-title":"The stimulation of TH2 cells results in increased IL-5 and IL-13 production via the H(4) receptor","volume":"79","author":"E Nikolouli","year":"2024","journal-title":"Allergy"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtos.2020.05.008","article-title":"Ocular surface disease associated with dupilumab treatment for atopic diseases","volume":"19","author":"C A Utine","year":"2021","journal-title":"Ocul Surf"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: A review of its use in the treatment of atopic dermatitis","volume":"78(3 Suppl\u20091)","author":"M J Gooderham","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.3390\/jcm14072487","article-title":"Ocular Side Effects of Dupilumab: A Comprehensive Overview of the Literature","volume":"14","author":"G Boscia","year":"2025","journal-title":"J Clin Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e12386","DOI":"10.1002\/clt2.12386","article-title":"Higher prevalence of dupilumab-induced ocular adverse events in atopic dermatitis compared to asthma: A daily practice analysis","volume":"14","author":"A R Schlosser","year":"2024","journal-title":"Clin Transl Allergy"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12348-024-00394-1","article-title":"Peripheral ulcerative keratitis associated with tralokinumab therapy: a case report and review of IL-13 inhibitor-associated ocular surface disease","volume":"14","author":"N Maganti","year":"2024","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1167\/iovs.14-15496","article-title":"IL-13 Stimulates Proliferation and Expression of Mucin and Immunomodulatory Genes in Cultured Conjunctival Goblet Cells","volume":"56","author":"J Tukler Henriksson","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"w30020","DOI":"10.4414\/SMW.2021.w30020","article-title":"Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients","volume":"151","author":"Y Guex-Crosier","year":"2021","journal-title":"Swiss Med Wkly"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/ICO.0000000000003162","article-title":"Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management","volume":"42","author":"T Mickevicius","year":"2023","journal-title":"Cornea"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"C A Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2751-3243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:34:31Z","timestamp":1776724471000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2751-3243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":23,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2026,4,20]]},"published-print":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2751-3243","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]}}}